België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

soho flordis uk ltd. - prunus africana, extract 25 mg; urticae dioicae, wortel, droog extract 300 mg - capsule, zacht - 25 mg - 300 mg - prunus africana, extract 25 mg; urticae dioicae, wortel, droog extract 300 mg

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires pharmaceutiques trenker - pharmaceutische laborator sa-nv - valeriana officinalis l., wortel, droog extractethanol 60% 4-6_1 500 mg - filmomhulde tablet - 500 mg - valeriana officinalis, wortel, droog extract 500 mg - valerianae radix

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tilman sa-nv - valeriana officinalis l., wortel, droog extractethanol 60% 4-6_1 500 mg - filmomhulde tablet - valeriana officinalis l., wortel, droog extractethanol 60% 4-6_1 500 mg - valerianae radix

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer santé familiale - valeriana officinalis l., wortel, droog extract 441,35 mg - omhulde tablet - valeriana officinalis l., wortel, droog extract 441.35 mg - valerianae radix

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vemedia manufacturing b.v. - valeriana, wortel, droog ethanol extract 70 3-6_1 450 mg - omhulde tablet - valeriana officinalis, wortel, droog extract 450 mg - valerianae radix

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vemedia manufacturing b.v. - valeriana, wortel, droog ethanol extract 70 3-6_1 125 mg - omhulde tablet - valeriana officinalis, wortel, droog extract 125 mg - valerianae radix

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vemedia manufacturing b.v. - humulus lupulus l., bloeiende toppen, droog extract, etoh, 40 %, 4-8_1 68 mg; valeriana officinalis l., wortel, droog extract, ethanol 70, 4-7_1 200 mg - omhulde tablet - valeriana officinalis, wortel, droog extract 200 mg; humulus lupulus, droog extract 68 mg

Europese Unie - Nederlands - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Europese Unie - Nederlands - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologicals voor aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Europese Unie - Nederlands - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals voor suidae - varkens (voor de mesterij) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.